Help Ensure Access to Paxlovid for COVID-19

You play a key role in limiting treatment delays with Paxlovid (nirmatrelvir/ritonavir) for patients with COVID-19.

Help HIGH-risk patients start within the 5-day window.

Dispensing. Any type of positive COVID-19 test is enough to qualify for Paxlovid, even a home test. And the med is still no cost to patients.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote